Calidi Biotherapeutics Inc (CLDI) Stock AnalysisCLDIStock AnalysisCalidi Biotherapeutics Inc

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Calidi Biotherapeutics Inc is currently not a good buy due to its significant financial losses and low price performance. The stock is trading at $1.32, down 93.01% year-to-date, and has an RSI of 38.409, indicating it is nearing oversold territory but not yet a strong buy signal. The company has reported consistent net losses, with a net income of -$4,416,000 in Q1 2026 and -$4,160,000 in Q2 2026, raising concerns about its financial stability. Additionally, the proposed 1-for-16 reverse stock split may not instill confidence among investors, as the stock is currently trading at a low price and has seen a 95% decline over the past year, suggesting a lack of market confidence in its recovery prospects.